Navigation Links
Summit Yields One-of-a-Kind Opportunity To Reduce Prescription Drug Overdoses
Date:11/16/2012

NEWARK, Del., Nov. 16, 2012 /PRNewswire-USNewswire/ --Today, a not-for-profit organization presenting at the Delaware Prescription Drug Abuse Summit appealed to the event's host, Attorney General Beau Biden, for assistance in preventing medication overdoses.  The Center for Lawful Access and Abuse Deterrence (CLAAD) asked Biden to work closely with his father, Vice President Joe Biden, to ensure that federal regulators properly implement Obama-Biden Administration drug policies. 

During CLAAD's presentation at the summit, Director Michael Barnes warned that pain medications without added safety features could flood back into communities in the coming weeks if the Food and Drug Administration (FDA) fails to follow the Obama-Biden strategy.

In recent years, the makers of the opioid pain relievers OxyContin and Opana removed their traditional products from the market in favor of new versions designed to impede certain forms of intentional abuse.  Preliminary, peer-reviewed evidence indicates that dealers and abusers have less interest in the new drugs with abuse-deterrent features.[1]  The new medications cost no more to consumers than their prior formulations. 

Several drug companies have asked the FDA for approval to bring the old, more readily abused formulations of the drugs back to the market as early as January 2013. 

"The Administration's prescription drug abuse prevention plan provides express support for abuse-deterrent medications," Barnes said.

Earlier this month, CLAAD and nine other public health and safety organizations sent a letter to the FDA urging it to implement Obama-Biden policy, foster the transition to abuse-deterrent medications, and prevent the marketing of generic versions of the drugs that do not have similar safety features.

"At today's summit, I asked General Biden to work closely with his father to make certain that the FDA does the right thing," Barnes said. 

Vice President Biden is considered one of the most accomplished national leaders in drug policy, having served as chairman of both the U.S. Senate Judiciary Committee and Drug Caucus.

"I have confidence that the Bidens will ensure that the FDA supports the shift to abuse-deterrent medications," Barnes concluded.  "We reached a turning point in our nation's prescription drug abuse epidemic at today's summit." 

[1] Cicero TJ, Ellis MS, Surratt HL. Effect of abuse-deterrent formulation of OxyContin. New England Journal of Medicine. 2012;367(2):187-189.


'/>"/>
SOURCE CLAAD
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. GHX Reveals Roadmap to Stronger Healthcare Community at GHX Healthcare Supply Chain Summit
2. Dehaier Medical to Present at the CFA 2012 Cross-Continental Summit on Investment in Shanghai
3. Next Generation Pharmaceutical Manufacturing Summit Pushes the Envelope of Thought-Leadership at its September Summit in London
4. Daniel Sontupe, SVP, Director of Market Access, at The CementBloc, to Present on Uncovering the Value in a Patient Support Program at CBI Summit
5. GDS Internationals Fourth Next Generation Pharmaceutical Drug Development Summit Attracts an Unprecedented Delegation of Thought Leaders
6. Cleveland Clinics 2012 Medical Innovation Summit Highlights Orthopaedic Technologies
7. Brand new Solid Form Co-Crystals and Amorphous Focus Morning at the Pharmaceutical Co-Crystals and Amorphous Material 2012 Summits
8. Online Career Service Holds Third Virtual Job Summit
9. FDAnews announces Third Annual Pharmaceutical Labeling Summit
10. VisionCare Implantable Telescope Technology Presentations Featured at Upcoming American Academy of Ophthalmology and Ophthalmology Innovation Summit Meetings
11. FDAnews announces Fifth Annual Risk Management & Drug Safety Summit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2017)... AccuGenomics, Inc., a diagnostic company based in ... the company has provided an AccuKit to the HIV ... Chapel Hill and to Qura Therapeutics for evaluation in ... HIV reservoir and viral expression in human CD4+ T ... Center is a joint initiative between the University of ...
(Date:8/8/2017)... Aug. 8, 2017  BioLineRx Ltd. (NASDAQ/TASE: BLRX), a ... reports its financial results for the second quarter ended ... the second quarter 2017 and to date: ... development programs for the Company,s lead project, BL-8040: ... study with BL-8040 as novel stem cell mobilization treatment ...
(Date:8/7/2017)... 2017  Diplomat Pharmacy, Inc. (NYSE: DPLO), the nation,s largest ... June 30, 2017.  All comparisons, unless otherwise noted, are to ... Second Quarter 2017 Highlights include: ... an increase of 3.5% Total prescriptions dispensed ... of 7.5% versus 7.6% Gross profit ...
Breaking Medicine Technology:
(Date:8/18/2017)... ... August 18, 2017 , ... More than 20,000 pairs of ... Congo (DRC) thanks to an ambitious venture that conjoined the passions of an NBA ... support of the Liberty community. These shoes will save lives from the rampant infections ...
(Date:8/18/2017)... ... August 18, 2017 , ... Mediaplanet today announces the launch ... lifestyles and highlighting the importance of proactive eye and ear health. The campaign ... latest innovations in hearing aid technology. , In this issue, the National ...
(Date:8/18/2017)... , ... August 18, 2017 , ... ... handling handheld devices. Through an educational webinar, they will present the line of ... chance to learn how easy you can automate everyday pipetting tasks. , Ideal ...
(Date:8/18/2017)... ... 2017 , ... Radabaugh & Associates, a family managed agency ... West Virginia, is embarking on a cooperative charity effort with the Chestnut Mountain ... Chestnut Mountain Ranch (CMR) is a Christ-centered boarding school for young men offering ...
(Date:8/18/2017)... ... August 18, 2017 , ... The Brian Gifford Agency, an ... is campaigning in support of Campagna Academy in a charity drive to provide for ... Boys’ Town of Indiana,” Campagna Academy is a nonprofit organization that has offered critical ...
Breaking Medicine News(10 mins):